WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Subject: search.filters.subject.metastasis

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Managing advanced prostate cancer in the Asia Pacific region: ``Real-world'' application of Advanced Prostate Cancer Consensus Conference 2019 statements
    (WILEY, 2022-01-01) Chiong, Edmund; Murphy, Declan G.; Buchan, Nicholas C.; Chua, Melvin L. K.; Hakim, Lukman; Hamid, Agus Rizal; Hong, Sung K.; Horvath, Lisa G.; Kanesvaran, Ravi; Khochikar, Makarand; Letran, Jason; Lojanapiwat, Bannakij; Malek, Rohan; Ng, Anthony C. F.; Vinh, Nguyen Tuan; Pang, See-Tong; Poon, Darren M. C.; Ong, Teng Aik; Saad, Marniza; Schubach, Kathryn; Shiroki, Ryoichi; Turkeri, Levent; Williams, Scott; Wong, Alvin; Ye, Dingwei; Davis, Ian D.; Grp, A.N.Z.U.P. Canc Trials
    Aim The second Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2020) gathered insights into the real-world application in the Asia-Pacific (APAC) region of consensus statements from the 3rd Advanced Prostate Cancer Consensus Conference (APCCC 2019). Methods The 4-h our virtual meeting in October 2020 brought together 26 experts from 14 APAC countries to discuss APCCC 2019 recommendations. Presentations were prerecorded and viewed prior to the meeting. A postmeeting survey gathered views on current practice. Results The meeting and survey highlighted several developments since APAC APCCC 2018. Increased access and use in the region of PSMA PET/CT imaging is providing additional diagnostic and staging information for advanced prostate cancer and influencing local and systemic therapy choices. Awareness of oligometastatic disease, although not clearly defined, is increasing. Novel androgen receptor pathway antagonists are expanding treatment options. Cost and access to contemporary treatments and technologies continue to be a significant factor influencing therapeutic decisions in the region. With treatment options increasing, multidisciplinary treatment planning, shared decision making, and informed choice remain critical. A discussion on the COVID-19 pandemic highlighted challenges for diagnosis, treatment, and clinical trials and new service delivery models that will continue beyond the pandemic. Conclusion APAC-specific prostate cancer research and data are important to ensure that treatment guidelines and recommendations reflect local populations and resources. Facilitated approaches to collaboration across the region such as that achieved through APAC APCCC meetings continue to be a valuable mechanism to ensure the relevance of consensus guidelines within the region.
  • No Thumbnail Available
    Item
    Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study
    (LIPPINCOTT WILLIAMS \& WILKINS, 2022-01-01) Arikan, Akif Enes; Makay, Ozer; Teksoz, Serkan; Vatansever, Safa; Alptekin, Husnu; Albeniz, Gurcan; Demir, Ali; Ozpek, Adnan; Tunca, Fatih
    Metastasis is the second most common type of adrenal gland mass. In patients undergoing follow-up for nonadrenal malignancy, adrenalectomy is performed when metastasis to adrenal gland is suspected on the basis of positron emission tomography-computed tomography (PET-CT) imaging. This study investigated the efficacy of PET-CT in the discrimination of metastatic lesions from nonmetastatic lesions in the adrenal glands. In this multicentric study, data was collected from enrolled centers. Forty-one patients who underwent surgery for suspected adrenal metastases were evaluated retrospectively. The following data types were collected: demographic, primary tumor, maximum standardized uptake value of adrenal mass (a-SUVx) and detectability in computed tomography and/or magnetic resonance imaging, and specimen size and histopathology. Six patients were excluded due to unavailability of PET-CT reports and 4 for being primary adrenal malignancy. The rest were divided into 2 groups (metastatic: n = 17, 55\% and nonmetastatic: n = 14, 45\%) according to histopathology reports. There was no statistical difference between the analyzed values, except the a-SUVx (P < .05). The a-SUVx cutoff value was defined as 5.50 by receiver operating characteristic curves and compared with literature. There was no statistical difference when each group was divided as low and high (P > .05). It was found that PET-CT was able to discriminate metastatic lesions from primary benign lesions (P = .022). PET-CT can discriminate primary benign lesions and metastatic lesions by cutoff 5.5 value for a-SUVx.
  • Thumbnail Image
    Item
    Retrospective analysis of melanoma patients who had undergone PET-CT examination
    (DERI ZUHREVI HASTALIKLAR DERNEGI, 2013-01-01) Bakar, Ozgur; Vardareli, Erkan; Sahin, Sedef; Yuksel, Selcen; Aksoy, Tamer
    Background and Design: Pet positivity was found in 21 (37.5\%) the incidence of melanoma is increasing significantly in Turkey and in the whole world. Thus, Positron Emission Tomography-Computed Tomography (PET-CT), which is being reimbursed by the government for the documentation of metastases of clinically suspicious patients with stages 1 b and higher, is becoming widely used. This study aims to analyze, the histopathological features of the tumors and the clinical and demographic data on melanoma patients who had undergone PET-CT examination for the screening of metastases. Materials and Methods: We collected data on 57 melanoma patients who had undergone PET-CT evaluation in the Nuclear Medicine Department between 2004 and 2011. On the basis of PET-CT positivity, we retrospectively analyzed SUV (Standard uptake value), demographic data, Breslow thickness, primary tumor location, presence of histopathologically documented ulceration, perineural, vascular and lymphatic invasion, and metastases detected by other screening methods as well as the proposed treatment modalities. Results: PET-CT positivity was found in 22 (39\%) patients. The mean Breslow thickness was 5.12 +/- 6.29mm., 1 patient (\%7) with <= 1mm, 5 (36\%) with 2-4mm and 8 patients (57\%) with >4mm of Breslow thickness had distant metastases. Statistically significant correlation was found between Breslow thickness and positive PET-CT findings. The distribution of the primary tumor site was 35.3\%left-sided, 25.5\%right-sided and 39.2\%on the midline. All patients with scalp involvement had distant metastases. There was no statistically significant correlation of PET-CT positivity with histopathologically proven ulceration and perineural, vascular and lymphatic invasion. Thirty-one percent positive correlation was found between Breslow thickness and SUV. Forty-five percent of PET-CT positive patients had metastases documented with other screening methods as well. All but 2 patients with distant metastases had undergone wide tumor resection and adjuvant chemotherapy or radiotherapy. Conclusion: PET-CT complementing conventional imaging methods gains much importance in the treatment planning for some selected high-risk melanoma patients